AU2017263574B2 - ASH1L inhibitors and methods of treatment therewith - Google Patents

ASH1L inhibitors and methods of treatment therewith Download PDF

Info

Publication number
AU2017263574B2
AU2017263574B2 AU2017263574A AU2017263574A AU2017263574B2 AU 2017263574 B2 AU2017263574 B2 AU 2017263574B2 AU 2017263574 A AU2017263574 A AU 2017263574A AU 2017263574 A AU2017263574 A AU 2017263574A AU 2017263574 B2 AU2017263574 B2 AU 2017263574B2
Authority
AU
Australia
Prior art keywords
compound
formula
substituted
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017263574A
Other languages
English (en)
Other versions
AU2017263574A1 (en
Inventor
Dmitry Borkin
Tomasz Cierpicki
Jing DENG
Jolanta Grembecka
Szymon Klossowski
Hao Li
Deanna MONTGOMERY
David ROGAWSKI
Marta SZEWCZYK
Jin ZHUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2017263574A1 publication Critical patent/AU2017263574A1/en
Application granted granted Critical
Publication of AU2017263574B2 publication Critical patent/AU2017263574B2/en
Priority to AU2023200873A priority Critical patent/AU2023200873B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2017263574A 2016-05-12 2017-05-12 ASH1L inhibitors and methods of treatment therewith Active AU2017263574B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200873A AU2023200873B2 (en) 2016-05-12 2023-02-16 ASH1L inhibitors and methods of treatment therewith

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662335160P 2016-05-12 2016-05-12
US62/335,160 2016-05-12
PCT/US2017/032365 WO2017197240A1 (en) 2016-05-12 2017-05-12 Ash1l inhibitors and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200873A Division AU2023200873B2 (en) 2016-05-12 2023-02-16 ASH1L inhibitors and methods of treatment therewith

Publications (2)

Publication Number Publication Date
AU2017263574A1 AU2017263574A1 (en) 2018-12-06
AU2017263574B2 true AU2017263574B2 (en) 2022-11-17

Family

ID=60266796

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017263574A Active AU2017263574B2 (en) 2016-05-12 2017-05-12 ASH1L inhibitors and methods of treatment therewith
AU2023200873A Active AU2023200873B2 (en) 2016-05-12 2023-02-16 ASH1L inhibitors and methods of treatment therewith

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200873A Active AU2023200873B2 (en) 2016-05-12 2023-02-16 ASH1L inhibitors and methods of treatment therewith

Country Status (8)

Country Link
US (2) US11883381B2 (https=)
EP (1) EP3454945B1 (https=)
JP (2) JP2019516700A (https=)
CN (1) CN109414596B (https=)
AU (2) AU2017263574B2 (https=)
CA (1) CA3024556A1 (https=)
ES (1) ES2910787T3 (https=)
WO (1) WO2017197240A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017254713C1 (en) 2016-04-22 2021-04-29 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of EGFR and methods of use
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
US10870648B2 (en) 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
AU2019348094B2 (en) * 2018-09-30 2022-12-22 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, preparation method, pharmaceutical composition and use thereof
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US20250101001A1 (en) * 2021-12-15 2025-03-27 Delix Therapeutics, Inc. Constrained amine psychoplastogens and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080246A (en) * 1965-07-22 1967-08-23 Twyford Lab Ltd 2-aryl-benzothiazole derivatives
US5124342A (en) * 1989-02-08 1992-06-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
WO1996037467A1 (en) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. N-benzylindol-3-yl butanoic acid derivatives as cyclooxygenase-2 inhibitors
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
WO2009051956A2 (en) * 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
WO2011018415A2 (en) * 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2015007615A1 (en) * 2013-07-18 2015-01-22 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
WO2015157313A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863A (en) 1848-10-17 Matthias p
US5861A (en) 1848-10-17 Locking umbrella and parasol
US510A (en) 1837-12-07 soeel
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
GB1093355A (en) * 1965-07-29 1967-11-29 Twyford Lab Ltd 2-carbamoylphenylbenzothiazoles
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5391452A (en) 1993-08-02 1995-02-21 Xerox Corporation Polyester toner and developer compositions
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DK1042287T3 (da) 1997-12-24 2005-08-15 Aventis Pharma Gmbh Indolderivater som inhibitorer af faktor Xa
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20080233101A1 (en) * 2005-09-15 2008-09-25 The Regents Of The University Of California RNA-mediated epigenetic regulation of gene transcription
CA2637933C (en) * 2006-01-24 2013-03-12 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
PT2057139E (pt) 2006-07-18 2013-12-05 Antibe Holdings Inc Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais
CN101583593A (zh) * 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2008094545A2 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009015067A2 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
KR102079404B1 (ko) * 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
US9889180B2 (en) 2012-11-19 2018-02-13 Agency For Science, Technology And Research Method of treating cancer
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3334733A1 (en) 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CA3018429A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080246A (en) * 1965-07-22 1967-08-23 Twyford Lab Ltd 2-aryl-benzothiazole derivatives
US5124342A (en) * 1989-02-08 1992-06-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
WO1996037467A1 (en) * 1995-05-22 1996-11-28 Merck Frosst Canada Inc. N-benzylindol-3-yl butanoic acid derivatives as cyclooxygenase-2 inhibitors
WO2007117465A2 (en) * 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
US20120053345A1 (en) * 2006-03-31 2012-03-01 Abbott Laboratories Indazole Compounds
WO2009051956A2 (en) * 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
WO2011018415A2 (en) * 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2015007615A1 (en) * 2013-07-18 2015-01-22 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
WO2015157313A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ANTONINI, I. et al., 'N*-N*-S* Tridentate ligand system as potential antitumor agents', J. Med. Chem 1981, vol 24, pages 1181-1184 *
CAS Registry Number 1016839-20-5; STN Entry Date 24 April 2008; 2-(5,6-Dimethyl-1H-benzimidazol-1-yl)-4-pyridinecarbothioamide. *
CAS Registry Number 1098353-30-0; STN Entry Date 1 February 2009; 3-(5-Bromo-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)benzenecarbothioamide. *
CAS Registry Number 1175743-53-9; STN Entry Date 26 August 2009; 4'-Methoxy[1,1'-biphenyl]-3-carbothioamide. *
CAS Registry Number 1175821-79-0; STN Entry Date 26 August 2009; 2'-Methoxy[1,1'-biphenyl]-3-carbothioamide. *
CAS Registry Number 1256482-80-0; STN Entry Date 14 December 2010; 3-(6-Methyl-1H-benzimidazol-2-yl)benzenecarbothioamide. *
CAS Registry Number 1256483-51-8; STN Entry Date 14 December 2010; 2-[3-(Aminothioxomethyl)phenyl]-1H-benzimidazole-6-carbothioamide. *
CAS Registry Number 1354756-48-1; STN Entry Date 31 January 2012; 3-(5-Chloro-2-benzoxazolyl)benzenecarbothioamide. *
CAS Registry Number 1354767-24-0; STN Entry Date 31 January 2012; 3-(5,7-Dichloro-2-benzoxazolyl)benzenecarbothioamide. *
CAS Registry Number 1409410-62-3; STN Entry Date 2 December 2012; 4-(5,6-Dimethyl-1H-benzimidazol-1-yl)-2-pyridinecarbothioamide. *
CAS Registry Number 1483179-12-9; STN Entry Date 28 November 2013 ; 6-(5,6-Dimethyl-1H-benzimidazol-1-yl)-2-pyridinecarbothioamide: *
CAS Registry Number 1778919-86-0; STN Entry Date 12 June 2015; 2-(5,6-Dimethyl-1H-benzimidazol-1-yl)-6-methyl-4-pyridinecarbothioamide. *
DUDLEY, DANETTE A. ET AL, JOURNAL OF MEDICINAL CHEMISTRY , 43(22), 4063-4070 CODEN: JMCMAR; ISSN: 0022-2623, (2000), doi:10.1021/JM000074L 10.1021/JM000074L *
DUMAITRE, BERNARD ET AL, JOURNAL OF MEDICINAL CHEMISTRY , 39(8), 1635-44 CODEN: JMCMAR; ISSN: 0022-2623, (1996), doi:10.1021/JM950812J 10.1021/JM950812J *
HELAL, AASIF ET AL, SPECTROCHIMICA ACTA, PART A: MOLECULAR AND BIOMOLECULAR SPECTROSCOPY , 105, 273-279 CODEN: SAMCAS; ISSN: 1386-1425, (2013), doi:10.1016/J.SAA.2012.12.034 10.1016/J.SAA.2012.12.034 *
KIM, HONG-SEOK ET AL, "Synthesis of crown ethers containing a thiazole subcyclic unit", JOURNAL OF HETEROCYCLIC CHEMISTRY , 36(5), 1285-1289 CODEN: JHTCAD; ISSN: 0022-152X, (1999), doi:10.1002/JHET.5570360528 10.1002/JHET.5570360528 *
KUMAR, VINOD ET AL, TETRAHEDRON LETTERS , 53(19), 2377-2379 CODEN: TELEAY; ISSN: 0040-4039, (2012), doi:10.1016/J.TETLET.2012.02.087 10.1016/J.TETLET.2012.02.087 *
KUTSUNUGI, Y. et al., ‘Photochromic properties of terarylene derivatives having a π-conjugation unit on central aromatic ring’, New J. Chem. 2009, vol. 33, pages 1368-1373 *
MCCLELLAND, ERNEST W. ET AL, "Dismutation of some disulphides", JOURNAL OF THE CHEMICAL SOCIETY 1095-1102 CODEN: JCSOA9; ISSN: 0368-1769, (1930), doi:10.1039/JR9300001095 10.1039/JR9300001095 *
MONDRAGON, ALEXANDER ET AL, TETRAHEDRON , 69(45), 9499-9506 CODEN: TETRAB; ISSN: 0040-4020, (2013), doi:10.1016/J.TET.2013.08.044 10.1016/J.TET.2013.08.044 *
SOSNICKI, JACEK ET AL, JOURNAL OF HETEROCYCLIC CHEMISTRY , 36(4), 1033-1041 CODEN: JHTCAD; ISSN: 0022-152X, (1999), doi:10.1002/JHET.5570360434 10.1002/JHET.5570360434 *
STANEK, JAROSLAV ET AL, JOURNAL OF MEDICINAL CHEMISTRY , 36(1), 46-54 CODEN: JMCMAR; ISSN: 0022-2623, (1993), doi:10.1021/JM00053A007 10.1021/JM00053A007 *
TAEUSCHER, ERIC ET AL, "Bis(4-hydroxythiazoles): novel functional and switchable fluorophores", SYNTHESIS , (14), 2334-2339 CODEN: SYNTBF; ISSN: 0039-7881, (2011), doi:10.1055/S-0030-1260670 10.1055/S-0030-1260670 *
VAN ZANDT, MICHAEL C. ET AL, BIOORGANIC & MEDICINAL CHEMISTRY , 12(21), 5661-5675 CODEN: BMECEP; ISSN: 0968-0896, (2004), doi:10.1016/J.BMC.2004.07.062 10.1016/J.BMC.2004.07.062 *
VON DER SAAL, WOLFGANG ET AL, ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) , 329(2), 73-82 CODEN: ARPMAS; ISSN: 0365-6233, (1996), doi:10.1002/ARDP.19963290204 10.1002/ARDP.19963290204 *
WANG, DECHUAN ET AL, "Studies on synthesis and iNOS/PAF dual inhibitory activity of dithiolane guanidine and amidine compounds", ZHONGGUO YAOKE DAXUE XUEBAO , 34(4), 296-301 CODEN: ZHYXE9; ISSN: 1000-5048, (2003) *
ZHANG, QIANG ET AL, "Discovery of Novel Triazole-Based Opioid Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY , 49(14), 4044-4047 CODEN: JMCMAR; ISSN: 0022-2623, (2006), doi:10.1021/JM0601250 10.1021/JM0601250 *

Also Published As

Publication number Publication date
EP3454945B1 (en) 2022-01-19
AU2023200873A1 (en) 2023-03-16
US20190142799A1 (en) 2019-05-16
JP7604006B2 (ja) 2024-12-23
JP2019516700A (ja) 2019-06-20
CN109414596B (zh) 2023-09-29
EP3454945A1 (en) 2019-03-20
EP3454945A4 (en) 2019-12-18
US20240245645A1 (en) 2024-07-25
ES2910787T3 (es) 2022-05-13
WO2017197240A1 (en) 2017-11-16
AU2023200873B2 (en) 2024-09-19
JP2022137128A (ja) 2022-09-21
US11883381B2 (en) 2024-01-30
CN109414596A (zh) 2019-03-01
CA3024556A1 (en) 2017-11-16
AU2017263574A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
AU2023200873B2 (en) ASH1L inhibitors and methods of treatment therewith
JP7789402B2 (ja) Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
US12364688B2 (en) NSD family inhibitors and methods of treatment therewith
US12466813B2 (en) PRC1 inhibitors and methods of treatment therewith
CA3084809C (en) Nsd family inhibitors and methods of treatment therewith

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)